Irbésartan/Hydrochlorothiazide Cristers

Irbesartan, the active ingredient in Irbésartan/Hydrochlorothiazide Cristers, is an Angiotensin II receptor blocker presented as a fixed‑dose oral tablet for oral use. It is combined with hydrochlorothiazide, a thiazide diuretic, to treat hypertension in adult patients.

GNH USA supplies Irbésartan/Hydrochlorothiazide Cristers as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is an antihypertensive combination that lowers elevated blood pressure through dual mechanisms. - Hypertension: provides sustained reduction of systolic and diastolic blood pressure in patients with primary hypertension. - Essential hypertension: improves blood‑pressure control when monotherapy is insufficient. - High blood pressure: assists in achieving target blood‑pressure goals as part of a comprehensive treatment plan.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urinary frequency - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal discomfort

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury or worsening renal function - Hyperkalemia or severe hypokalemia - Angioedema or severe allergic reaction - Significant hypotension leading to syncope - Blood dyscrasias such as agranulocytosis

Patients should be monitored for safety and appropriate use. - Blood pressure monitoring: check regularly to ensure therapeutic response. - Renal function assessment: evaluate serum creatinine and eGFR before and during therapy. - Electrolyte surveillance: monitor potassium and sodium levels, especially with concomitant drugs. - Pregnancy avoidance: contraindicated in pregnancy due to fetal risk. - Elderly caution: start at lower dose and monitor for orthostatic hypotension. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid): - Aliskiren: combined use can increase risk of renal impairment and hyperkalemia. - Lithium: thiazide component may raise lithium levels, leading to toxicity. - ACE inhibitors or other ARBs: additive effects on potassium and renal function. - Potassium‑sparing diuretics or supplements: risk of hyperkalemia. - NSAIDs: may blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely): - Other diuretics: monitor electrolytes and volume status. - Antihypertensive agents (beta‑blockers, calcium channel blockers): may enhance blood‑pressure lowering. - CYP2C9 inhibitors (e.g., fluconazole): can increase irbesartan plasma concentrations. - Antidiabetic drugs: diuretic‑induced changes in glucose may require dose adjustment.